# Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease

> **NCT00863434** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 2 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Recurrent Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** clofarabine
- **DRUG:** cytarabine
- **BIOLOGICAL:** filgrastim

## Key facts

- **NCT ID:** NCT00863434
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2011-02
- **Final completion:** —
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863434, "Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00863434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*